Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains
NCT ID: NCT02718157
Last Updated: 2021-05-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
771 participants
INTERVENTIONAL
2016-08-10
2017-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Colonization with Group B Streptococcus During Pregnancy
NCT03671486
Development and Optimization of a GBS Diagnostic Test
NCT00322829
Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study
NCT00330642
Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor
NCT02511444
Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study
NCT00920530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The GenePOC GBS Test utilizes automated sample preparation and real-time polymerase chain reaction (PCR) to detect a cfb gene sequence specific to the Streptococcus agalactiae genome. The GenePOC GBS Test is indicated for the identification of antepartum GBS colonization and does not provide susceptibility results. Culture isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women.
The GenePOC GBS is an IVD system is comprised of the GenePOC Diagnostics System and the GenePOC Group B Step \[GBS\] Test, the components of which are:
1. Instrument
2. GBS disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge)
3. GBS Sample Buffer Tube (SBT)
4. Sample Transfer Device (STD).
The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination.
Lim Broth is used for the selective enrichment of group B streptococci (Streptococcus agalactiae). An aliquot of the broth is mixed with GenePOC Sample Buffer Tube Reagent (SBT), after which a sample is transferred to the GenePOC GBS PIE. The GenePOC GBS PIE is then automatically processed by the GenePOC Instrument.
On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures.
One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from four (4) Clinical Centers to obtain a total of 150 specimens positive for GBS based on the Reference Method final result.
Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Accuracy Testing
Comparison between GenePOC PCR and Reference Method
Comparison between GenePOC PCR and Reference Method
Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comparison between GenePOC PCR and Reference Method
Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years old and more
* Being at a gestation period of 35 to 37 weeks.
* Vaginal/rectal swab specimen
* Transport and storage times, and conditions (e.g. room temperature and/or refrigerated) within the labeled indications.
* Fresh specimens available to be tested with the GenePOC GBS System within 96 hours (4 days) of collection if kept at 2-25°C
* Fresh specimens must be tested with the Reference Method within 96 hours (4 days) of collection if kept at 2-25°C
* The GenePOC GBS System and the Reference Method will be performed according to the GenePOC GBS Investigation Documents.
* Materials use within their expiration date
* The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents.
Exclusion Criteria
* Less than 18 years old
* Gestation not between 35-37 weeks
* Transport and storage times and conditions that exceed these Study Protocol requirements
* The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents
* Materials used beyond their expiration date
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meridian Bioscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrice Allibert
Role: STUDY_DIRECTOR
Meridian Bioscience, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Detroit Medical Center University Laboratories
Detroit, Michigan, United States
Tricore Laboratory University of New Mexico
Albuquerque, New Mexico, United States
Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
Toronto, Ontario, Canada
CHU de Québec - Université Laval
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GenePOC-GBS_clinical-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.